JP2022523656A5 - - Google Patents
Info
- Publication number
- JP2022523656A5 JP2022523656A5 JP2021542146A JP2021542146A JP2022523656A5 JP 2022523656 A5 JP2022523656 A5 JP 2022523656A5 JP 2021542146 A JP2021542146 A JP 2021542146A JP 2021542146 A JP2021542146 A JP 2021542146A JP 2022523656 A5 JP2022523656 A5 JP 2022523656A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- administered
- use according
- kir3dl2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795194P | 2019-01-22 | 2019-01-22 | |
| US62/795,194 | 2019-01-22 | ||
| PCT/EP2020/051234 WO2020152081A1 (en) | 2019-01-22 | 2020-01-20 | Treatment of t cell lymphoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523656A JP2022523656A (ja) | 2022-04-26 |
| JP2022523656A5 true JP2022523656A5 (https=) | 2023-01-30 |
| JP7611834B2 JP7611834B2 (ja) | 2025-01-10 |
Family
ID=69187765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542146A Active JP7611834B2 (ja) | 2019-01-22 | 2020-01-20 | Ｔ細胞リンパ腫の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12448442B2 (https=) |
| EP (1) | EP3914620B1 (https=) |
| JP (1) | JP7611834B2 (https=) |
| KR (1) | KR20210119454A (https=) |
| CN (1) | CN113784979B (https=) |
| AU (1) | AU2020210710B2 (https=) |
| BR (1) | BR112021014236A2 (https=) |
| CA (1) | CA3125945A1 (https=) |
| DK (1) | DK3914620T3 (https=) |
| ES (1) | ES3062709T3 (https=) |
| MX (1) | MX2021008686A (https=) |
| WO (1) | WO2020152081A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2878749T3 (es) | 2013-02-20 | 2021-11-19 | Innate Pharma | Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico |
| KR102345173B1 (ko) | 2014-03-14 | 2021-12-29 | 이나뜨 파르마 에스.에이. | 증가된 안정성을 가진 인간화 항체 |
| KR20230165913A (ko) * | 2021-04-05 | 2023-12-05 | 이나뜨 파르마 에스.에이. | 면역조직화학 방법 및 kir3dl2-특이적 시약 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| AU2002219229B2 (en) | 2000-12-18 | 2007-12-20 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Means for the diagnosis and therapy of CTCL |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DK1534335T4 (en) | 2002-08-14 | 2015-10-05 | Macrogenics Inc | FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| JP5367982B2 (ja) | 2004-04-16 | 2013-12-11 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| PL2573114T3 (pl) | 2005-08-10 | 2016-10-31 | Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania | |
| EP1999470A4 (en) | 2006-03-10 | 2009-08-19 | Macrogenics Inc | IDENTIFICATION AND GENETIC MODIFICATION OF ANTIBODIES WITH HEAVY CHAINS OF VARIANTS AND METHODS OF USE THEREOF |
| WO2008105886A2 (en) | 2006-05-26 | 2008-09-04 | Macrogenics, Inc. | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| ES2539045T3 (es) | 2009-01-19 | 2015-06-25 | Innate Pharma | Anticuerpos anti-KIR3D |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX369148B (es) | 2012-09-19 | 2019-10-30 | Innate Pharma | Agentes de unión kir3dl2. |
| WO2014044681A1 (en) | 2012-09-19 | 2014-03-27 | Innate Pharma | Kir3dl2 binding agents |
| ES2878749T3 (es) | 2013-02-20 | 2021-11-19 | Innate Pharma | Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico |
| US20160130346A1 (en) * | 2013-05-29 | 2016-05-12 | Institut National De La Sante Et De La Recherche Medicale | Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas |
| KR102345173B1 (ko) | 2014-03-14 | 2021-12-29 | 이나뜨 파르마 에스.에이. | 증가된 안정성을 가진 인간화 항체 |
| EP3529277A1 (en) | 2016-10-21 | 2019-08-28 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| US11848990B2 (en) | 2021-10-15 | 2023-12-19 | Siden, Inc. | Method and system for distributing and storing content using local clouds and network clouds |
-
2020
- 2020-01-20 JP JP2021542146A patent/JP7611834B2/ja active Active
- 2020-01-20 MX MX2021008686A patent/MX2021008686A/es unknown
- 2020-01-20 KR KR1020217026398A patent/KR20210119454A/ko active Pending
- 2020-01-20 BR BR112021014236-3A patent/BR112021014236A2/pt unknown
- 2020-01-20 EP EP20701559.5A patent/EP3914620B1/en active Active
- 2020-01-20 AU AU2020210710A patent/AU2020210710B2/en active Active
- 2020-01-20 DK DK20701559.5T patent/DK3914620T3/da active
- 2020-01-20 WO PCT/EP2020/051234 patent/WO2020152081A1/en not_active Ceased
- 2020-01-20 ES ES20701559T patent/ES3062709T3/es active Active
- 2020-01-20 CA CA3125945A patent/CA3125945A1/en active Pending
- 2020-01-20 CN CN202080014835.6A patent/CN113784979B/zh active Active
-
2021
- 2021-07-21 US US17/381,418 patent/US12448442B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527572A5 (https=) | ||
| Boulikas et al. | Cisplatin and platinum drugs at the molecular level | |
| JP2022523656A5 (https=) | ||
| Ducreux et al. | A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma | |
| Liu et al. | Recent updates on Sintilimab in solid tumor immunotherapy | |
| JP2015532292A5 (https=) | ||
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2018522851A5 (https=) | ||
| JP2019517498A5 (https=) | ||
| JP2021518408A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| JP2021528438A5 (https=) | ||
| JP2021530444A5 (https=) | ||
| Gornet et al. | Exacerbation of oxaliplatin neurosensory toxicity following surgery | |
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| JP2008540364A5 (https=) | ||
| JP2022502508A5 (https=) | ||
| US20090196871A1 (en) | Use of 4-pyridylmethylphthalazines for cancer treatment | |
| JP2024527974A5 (https=) | ||
| McKeage | Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation | |
| JP2022513072A5 (https=) | ||
| Machida et al. | Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| Li et al. | Critical considerations in the administration of antineoplastic therapy for patients with malignant solid tumors undergoing hemodialysis |